A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy RSV and PIV3 seropositive 1-9 year-old children

Trial Profile

A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy RSV and PIV3 seropositive 1-9 year-old children

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2009

At a glance

  • Drugs MEDI 534 (Primary)
  • Indications Parainfluenza virus infections; Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2009 Results published in The Pediatric Infectious Disease Journal.
    • 02 May 2008 Results presented at PAS 2008.
    • 30 Jul 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top